HeartMate 3桥接心脏移植的早期结局
基于OPTN数据库,比较HM2、HVAD和HM3三种连续流左心室辅助装置桥接移植的成人受者早期结局。移植后6个月全因死亡率在三组间相似(HM2 5.9%、HVAD 7.7%、HM3 4.7%,log-rank p=0.30)。HM3无泵血栓事件,移植时群体反应性抗体较低,但6个月移植物排斥率无差异。
要点
- HM3桥接移植后6个月死亡率与HM2、HVAD相似。
- HM3无泵血栓事件,HVAD移植前装置故障率最低。
- HM3移植时群体反应性抗体较低,但排斥率无差异。
核心结论
- HM3作为桥接移植提供良好的早期结局,可能与合并症减少相关。
- 需要更长随访以明确耐久性左心室辅助装置间的差异。
研究设计与样本
- 使用器官获取与移植网络数据库的回顾性队列研究。
- 纳入2015年4月1日至2018年1月31日期间计划以连续流左心室辅助装置(HM2、HVAD或HM3)桥接移植的成人患者。
- 共1978例患者成功桥接移植:HM2 881例、HVAD 920例、HM3 177例。
- 主要终点为移植后6个月全因死亡率,采用Cox比例风险模型分析桥接装置的独立影响。
主要发现
- 移植后6个月死亡率三组相似:HM2 5.9%、HVAD 7.7%、HM3 4.7%(log-rank p=0.30)。
- HM2患者平均左心室辅助装置支持时间延长2个月(p<0.01)。
- HVAD移植前装置更换率最低(p=0.01)。
- HM3无泵血栓事件(p<0.01)。
- HVAD移植前装置故障率最低(p<0.01)。
临床怎么用
- HM3可作为桥接移植的可靠选择,早期生存与HM2、HVAD相当。
- HM3无泵血栓事件可能有利于减少桥接期间血栓相关并发症。
- HM3移植时群体反应性抗体较低,但需关注远期排斥风险。
局限性
- 回顾性数据库研究,存在选择偏倚可能。
- HM3样本量较小(177例),随访时间有限。
- 需要更长随访以评估远期结局差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Left ventricular assist devices are increasingly used as bridge-to-transplantation in eligible patients. The HeartMate 3 (HM3; Abbott Laboratories, Abbot Park, IL) is the latest device to obtain US Food and Drug Administration approval as bridge-to-transplantation. This study examines early outcomes of transplant recipients after HM3 in comparison with recipients bridged with the HeartMate 2 (HM2; Abbott Laboratories) and HeartWare Ventricular Assist System (HVAD; Medtronic, Minneapolis, MN) devices. METHODS: Using the Organ Procurement and Transplantation Network database, we identified all adult patients who were slated for bridge-to-transplantation with a continuous-flow left ventricular assist devices (HM2, HVAD, or HM3) between April 1, 2015 and January 31, 2018. The primary endpoint was all-cause mortality 6 months after transplantation. The independent influence of the bridging device on outcomes was determined using Cox proportional hazard models. RESULTS: Patients (N = 1,978) were successfully bridged to transplantation with the HM2 (n = 881), HVAD (n = 920), or HM3 (n = 177) device. Six-month mortality rates were similar across these devices (HM2, 5.9%; HVAD, 7.7%; HM3, 4.7%; log-rank p = 0.30). On average HM2 patients were on a left ventricular assist device for 2 months longer (p < 0.01). The HVAD had the lowest rate of device exchange before transplant (p = 0.01). The HM3 had no events of pump thrombosis (p < 0.01). HVAD patients had the lowest rate of device malfunction before to transplant (p < 0.01). Panel reactive antibodies at the time of transplantation were lower for HM3 patients (p < 0.01); however rates of graft rejection at 6 months were not different (p = 0.25). CONCLUSIONS: The HM3 device provides excellent early outcomes as a bridge to transplantation and may be associated with a reduction in comorbidities. Longer follow-up is needed to better define differences between durable left ventricular assist devices.
引用
- Suarez-Pierre A, Lui C, Zhou X, et al. Early Outcomes After Heart Transplantation in Recipients Bridged With a HeartMate 3 Device. Ann Thorac Surg. 2019. PMID: 30880137. doi:10.1016/j.athoracsur.2019.01.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。